Equity Analysis /
United States of America

US : InflaRx N.V. - IFRX | Phase 3 Hidradenitis Suppurativa Strategy is Solid

    Contributors
    Timur Ivannikov
    Ryan Deschner
    CGS-CIMB
    5 January 2022
    Published byCGS-CIMB